4.7 Review

Advancing precision medicine with personalized drug screening

期刊

DRUG DISCOVERY TODAY
卷 24, 期 1, 页码 272-278

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.08.010

关键词

-

资金

  1. National Institutes of Health Intramural Research Program at the National Center for Advancing Translational Sciences
  2. NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [ZIATR000018] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Personalized drug screening (PDS) of approved drug libraries enables rapid development of specific small-molecule therapies for individual patients. With a multidisciplinary team including clinicians, researchers, ethicists, informaticians and regulatory professionals, patient treatment can be optimized with greater efficacy and fewer adverse effects by using PDS as an approach to find remedies. In addition, PDS has the potential to rapidly identify therapeutics for a patient suffering from a disease without an existing therapy. From cancer to bacterial infections, we review specific maladies addressed with PDS campaigns. We predict that PDS combined with personal genomic analyses will contribute to the development of future precision medicine endeavors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据